Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
N/A
1(33.3%)
3Total
Phase 2(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07733531Not ApplicableNot Yet Recruiting

Self-Compassion, Health, and Empowerment

Role: lead

NCT03503864Phase 2Active Not Recruiting

Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma

Role: lead

NCT06088030Phase 2Recruiting

Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer

Role: lead

All 3 trials loaded